Novavax, Inc. (NVAX) - Earnings growth in current year

The 12-month earnings per share growth rates correlate with the optimization of global vaccine distribution, where site diversification mitigates risks. The value of -101.60 defines the current metric, while strategic platform licensing ensures capital inflows. The financial results of Novavax, Inc. (NVAX) rely on the sale of innovative influenza and coronavirus drugs developed using recombinant nanoparticles.

NVAX Novavax Pharma Earnings per share growth in current year (07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Novavax (NVAX)

- stock price and consensus target price:

Price Performance Chart Novavax, Inc.|NVAX - Consensus Target

- market capitalization indicators:

Market Capitalization Novavax, Inc.|NVAX - Total Company Value

- book capitalization data:

Net Assets per Share Novavax|NVAX - Company Book Value|Capitalization to Book Value Ratio novavax.com|NVAX - Aggregate Company Assets

- debt and liquidity details:

- earnings and multiples data:

NVAX - Net Income|Net Profit Forecast Novavax, Inc.|NVAX - Price to Earnings Ratio|Future Price to Earnings Multiple Novavax, Inc.|NVAX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Novavax, Inc.|NVAX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Novavax|NVAX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months novavax.com|NVAX - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Novavax, Inc.

- revenue and sales proceeds data:

NVAX - Company Revenue|Company Revenue Forecast Novavax, Inc.|NVAX - Market Cap to Revenue|Price-to-Projected Revenue Ratio Novavax|NVAX - Sales Growth YoY (TTM)

Fundamental valuation:Novavax, Inc.

The ability of Novavax, Inc. (NVAX) to commercialize new vaccines amidst fierce competition determines the long-term viability of the business. By analyzing the year-over-year change in EPS, an investor can track the dynamics of net income per share, which allows for an assessment of cost management efficiency and the pace of profitability recovery following the pandemic slump to determine the asset's fair value.

Key competitors